- Rokote Laboratories partners with 3PBIOVIAN to manufacture the FINCoVac 2.1 intranasal COVID-19 vaccine for Phase I clinical trials.
- 3PBIOVIAN will provide GMP manufacturing services using their adenovirus vector process expertise.
3PBIOVIAN, a pan-European biologics CDMO, has recently partnered with Rokote Laboratories, a vaccine development company, to produce GMP batches of their adenovirus vector-based COVID-19 vaccine, FINCoVac 2.1. This vaccine is designed to induce a strong mucosal immune response in the nasopharyngeal cells, the primary entry point for the SARS-CoV-2 virus.
The agreement covers the production of both the Drug Substance and Drug Product for the vaccine, which will be used in upcoming Phase I clinical studies. Manufacturing will be conducted at 3PBIOVIAN’s facilities in Turku, Finland, utilising their standard adenovirus vector process. Due to the urgent nature of the project, the program has been expedited to produce a GMP batch in a short timeframe, leveraging 3PBIOVIAN’s extensive experience in adenovirus-based manufacturing.
Rokote Laboratories, a Finnish biotechnology company, focuses on developing intranasal vaccines that target mucosal immunity. The FINCoVac 2.1 vaccine is their latest effort to create an easy-to-administer nasal spray that could prevent both COVID-19 infection and transmission.
“We are pleased to partner with 3PBIOVIAN for the manufacturing of our next-generation intranasal COVID-19 vaccine,” said Erkko Ylösmäki, CEO of Rokote Laboratories. “The ability to use 3PBIOVIAN’s standard process for rapid GMP batch production, along with their extensive experience with adenovirus-based processes, made 3PBIOVIAN the ideal CDMO partner.”
Antti Nieminen, Deputy CEO at 3PBIOVIAN, expressed enthusiasm for the collaboration, stating, “We are delighted that Rokote Laboratories has selected us as a partner for the manufacturing of their Adenovirus-based innovative drug candidate.”
Overview of outsourcing trends 
